Dr. Hermênio Lima
Dr. Hermênio Lima is a dermatologist and immunologist and the director at the division of dermatology at McMaster University. Dr. Lima is a member of the American Academy of Dermatology, the Canadian Dermatology Association, the Canadian Society of Allergy and Clinical Immunology, and the Brazilian Society of Dermatology. His main research interests are in the area of Immunodermatology and he has published numerous articles in this field. He has mentored many medical residents in Brazil.
Saturday APR 9, 2022
What’s New in Type 2?
Type 2 Inflammation Is the Predominant Inflammatory pathway driving Atopic dermatitis, and its understanding in AD and other Dermatological conditions continues to evolve. There are novel concepts where research is progressing such as barrier function, microbiome and neuroimmune mechanisms of itch. The arrival of novel agents specifically targeting T2i was a breakthrough around five years ago. We can now understand the long-term impact of specifically targeting the T2i pathway. There are also new dermatological diseases beyond AD where we now know T2i is playing an important role in pathophysiology.
- Review research updates on barrier dysfunction and in the pathophysiology of AD
- Review latest data in long term control of moderate to severe AD
- Review Type 2 inflammation as a therapeutic target in dermatologic diseases outside of AD